Getinib Tablet 250 mg contains Gefitinib, an oral targeted therapy used in the treatment of certain types of non-small cell lung cancer (NSCLC). Gefitinib belongs to the class of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, which block the activity of EGFR—a protein that promotes cancer cell growth and division. By inhibiting EGFR, Getinib helps slow tumor growth, reduce cancer progression, and improve patient outcomes in EGFR mutation-positive NSCLC.

This oral formulation provides a convenient option for patients, allowing targeted therapy without the need for intravenous administration, and is particularly valuable in patients with advanced or metastatic NSCLC.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Getinib Tablet 250 mg is indicated for:

• Advanced or metastatic non-small cell lung cancer (NSCLC) in patients with confirmed EGFR-activating mutations

• Patients who have progressed after chemotherapy or are unsuitable for platinum-based chemotherapy

• As first-line therapy for EGFR mutation-positive NSCLC to control tumor growth and disease progression

Gefitinib is specifically effective against tumors that rely on EGFR signaling for survival and proliferation, making genetic testing for EGFR mutation an important prerequisite before initiating treatment.

Dosage and Administration

• Adults: The standard dose is one 250 mg tablet once daily, taken orally with or without food

• Swallow the tablet whole with water; do not crush or chew

• Take at the same time each day to maintain consistent blood levels

• Continue therapy until disease progression or unacceptable toxicity occurs

• Regular monitoring of liver function, lung status, and overall health is recommended during treatment

Benefits

• Targeted therapy selectively inhibits EGFR, reducing tumor growth while sparing healthy cells

• Oral administration allows convenient outpatient treatment

• Effective in EGFR mutation-positive NSCLC, providing improved progression-free survival

• Can be used as first-line therapy in patients unsuitable for chemotherapy

• May improve quality of life by controlling symptoms associated with tumor progression, such as cough, shortness of breath, and chest discomfort

Side Effects

Getinib may cause side effects, which can range from mild to severe:

• Common: diarrhea, skin rash, acne, dry skin, nausea, vomiting

• Less common: fatigue, loss of appetite, mild liver enzyme elevation

• Rare but serious: interstitial lung disease (ILD), severe liver toxicity, ocular disturbances

Patients should report persistent diarrhea, severe rash, breathing difficulties, or jaundice immediately to a healthcare professional. Dose adjustments or temporary discontinuation may be required for severe side effects.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions

• Do not use in patients with known hypersensitivity to Gefitinib or excipients

• Monitor liver function regularly; avoid in severe hepatic impairment

• Use cautiously in patients with lung disease or interstitial lung disease history

• Pregnancy and breastfeeding are contraindicated unless advised by a physician

• Avoid co-administration with strong CYP3A4 inducers or inhibitors that may affect drug levels

Storage

Store in a cool, dry place below 30°C, protected from moisture and light. Keep out of reach of children.

Getinib Tablet 250 mg (Gefitinib) is a targeted oral therapy for EGFR mutation-positive NSCLC, offering effective tumor control, convenient administration, and a well-established safety profile under proper medical supervision.